* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download End TB Strategy - pulmonology kkm
Survey
Document related concepts
Neglected tropical diseases wikipedia , lookup
Herd immunity wikipedia , lookup
Neonatal infection wikipedia , lookup
Globalization and disease wikipedia , lookup
Whooping cough wikipedia , lookup
Onchocerciasis wikipedia , lookup
Schistosomiasis wikipedia , lookup
Vaccination policy wikipedia , lookup
Hepatitis B wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Sociality and disease transmission wikipedia , lookup
Immunocontraception wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Coccidioidomycosis wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Transcript
End TB Strategy 1995 HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only Full implementation of Global Plan: 2015 MDG target reached but TB not eliminated by 2050 Current rate of decline -2%/yr China, Cambodia -4%/yr W Europe after WWII 10%/yr Elimination target:<1 / million / yr -20%/yr Projected acceleration of TB incidence decline to target levels Current global trend: -2%/year Average -10%/year Optimize current tools, pursue universal health coverage and social protection Introduce new vaccine, new prophylaxis -5%/year Average -17%/year DRAFT Post-2015 TB Strategy at a glance VISION: A WORLD FREE OF TB Zero deaths, disease and suffering due to TB GOAL: End the Global TB Epidemic TARGETS FOR 2035: 95% reduction in TB deaths (compared with 2015) 90% reduction in TB incidence rate (<10/100,000) MILESTONES FOR 2025: 75% reduction in TB deaths (compared with 2015) 50% reduction in TB incidence rate (< than 55/100,000) No affected families face catastrophic costs due to TB Pillar 1: Innovative TB care • Rapid diagnosis of TB including universal drug susceptibility testing;systematic screening of contacts and high-risk groups • Treatment of all forms of TB including drug-resistant TB, with patient support • Collaborative TB/HIV activities and management of co- morbidities • Preventive treatment for high-risk groups and vaccination of children Pillar 2: Bold Policies and Supportive Systems • Government stewardship, commitment, and adequate resources for TB care and control with monitoring and evaluation • Engagement of communities, civil society organizations, and all public and private care providers • Regulatory framework for vital registration, case notification, drug quality and rational use, and infection control • Universal Health Coverage, social protection and other measures to address social determinants of TB Pillar 3: Intensified Research and Innovation • Discovery, development and rapid uptake of new diagnostics, drugs and vaccines • Operational research to optimize implementation and adopt innovations Tools required for eradication in our lifetime: A potent regimen for treatment Assessment of fluoroquinolone trials in early 2014 Three trials: OFLOTUB/Gatifloxacin for TB Phase III trial: gatifloxacin substituted for ethambutol – 4 months Rx results expected second half 2013 ReMox: moxifloxacin substituted for ethambutol or isoniazid – 4 months Rx - results expected early 2014 Rifaquin trial: moxifloxacin substituted for ethambutol (intensive phase), associated with rifapentine once weekly in continuation phase – presentation at CROI 2013. 4-month arm did not work NC-001 regimen: PA-824, pyrazinamide, moxifloxacin Tools required for eradication in our lifetime: Vaccines Mass vaccination with a potent vaccine: – pre-exposure: would prevent infection to occur, and therefore disease, but impact would take a long time to appear – post-exposure: would prevent “reactivation”, and would have impact on transmission as new cases will not emerge any longer out of the pool of already infected. However, it would not prevent new infection Mobile technology could be game-changer in fight against TB Stop TB partnership 28 May 2012